Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 01:15PM EDT. Market open.
| Previous Close | 51.18 |
| Open | 50.90 |
| Bid | 51.62 x 100 |
| Ask | 51.80 x 100 |
| Day's Range | 50.87 - 51.79 |
| 52 Week Range | 50.27 - 75.74 |
| Volume | |
| Avg. Volume | 1,768,538 |
| Market Cap | 11.611B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 19.52 |
| EPS (TTM) | 2.65 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 74.29 |
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksBiotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
ZacksAllogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.